Wellington Management Group LLP Sells 510,264 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Wellington Management Group LLP lowered its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,061,996 shares of the biopharmaceutical company’s stock after selling 510,264 shares during the quarter. Wellington Management Group LLP owned approximately 10.08% of Sage Therapeutics worth $131,363,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in SAGE. Swiss National Bank lifted its holdings in shares of Sage Therapeutics by 1.0% in the third quarter. Swiss National Bank now owns 118,200 shares of the biopharmaceutical company’s stock worth $2,433,000 after acquiring an additional 1,200 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Sage Therapeutics by 4.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 408,987 shares of the biopharmaceutical company’s stock valued at $8,417,000 after buying an additional 17,819 shares during the last quarter. UBS Group AG raised its holdings in Sage Therapeutics by 27.8% in the 3rd quarter. UBS Group AG now owns 102,739 shares of the biopharmaceutical company’s stock valued at $2,114,000 after buying an additional 22,358 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Sage Therapeutics in the 3rd quarter valued at approximately $360,000. Finally, Federated Hermes Inc. bought a new position in Sage Therapeutics in the 3rd quarter valued at approximately $3,416,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Trading Down 0.7 %

NASDAQ SAGE opened at $10.67 on Friday. The company has a fifty day simple moving average of $12.25 and a 200 day simple moving average of $18.65. Sage Therapeutics, Inc. has a 12-month low of $9.76 and a 12-month high of $56.37. The company has a market cap of $642.12 million, a P/E ratio of -1.27 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The firm had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. Sage Therapeutics’s revenue was up 139.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.46) earnings per share. Sell-side analysts predict that Sage Therapeutics, Inc. will post -6.46 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on SAGE. Baird R W upgraded shares of Sage Therapeutics to a “hold” rating in a report on Wednesday, May 29th. Mizuho lowered their price target on shares of Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Friday, April 26th. JPMorgan Chase & Co. lowered their price target on shares of Sage Therapeutics from $28.00 to $23.00 and set an “overweight” rating for the company in a report on Thursday. The Goldman Sachs Group lowered their price target on shares of Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, April 26th. Finally, Wedbush reaffirmed a “neutral” rating and set a $24.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, April 17th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $34.80.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.